Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus capecitabine versus bevacizumab alone as maintenance therapy in HER2-negative metastatic breast cancer
2008-006872-31Phase 3Suspended
- Sponsor
- Roche
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, capecitabine and docetaxel in breast cancer and breast cancer (BC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Mar 2009; status: suspended.
02
Drugs
bevacizumabcapecitabinedocetaxel
03
Conditions
breast cancerbreast cancer (BC)
Beyond the preview
Go deeper on 2008-006872-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006872-31.